Wednesday, March 13, 2013

Merck forges on with Vytorin trial after safety review - PMLiVE


Merck & Co has elected to press on with a controversial study of its combination cholesterol treatment Vytorin that has already cost it nearly $690m to settle securities lawsuits.
The IMPROVE-IT study is comparing Vytorin (simvastatin and ezetimibe) to Zocor (simvastatin) in 18,000 patients and has been cleared to continue after an independent monitoring board concluded there were no safety issues.

Posted via email from Jack's posterous

No comments: